Literature DB >> 21232602

Reduced somatostatin in subgenual anterior cingulate cortex in major depression.

Adam Tripp1, Rama S Kota, David A Lewis, Etienne Sibille.   

Abstract

Converging evidence suggests a central role for dysfunction of the subgenual anterior cingulate cortex (sgACC) in the pathophysiology of major depressive disorder (MDD). Underlying mechanisms may include altered GABAergic function. Expression of somatostatin (SST), an inhibitory neuropeptide localized to a subset of GABA neurons, has been shown to be lower in the dorsolateral prefrontal cortex of male MDD subjects. Here, to investigate whether alterations in SST may contribute to sgACC dysfunction in MDD, and whether the alterations display sex-specificity, we measured sgACC SST at the mRNA and precursor peptide levels in a large cohort of subjects with MDD. SST mRNA levels were analyzed by quantitative PCR (qPCR) in the postmortem sgACC from male (n=26) and female (n=25) subjects with MDD and sex-matched subjects with no psychiatric diagnosis (n=51). Prepro-SST protein levels were assessed in a subset of subjects (n=42 pairs) by semi-quantitative Western blot. The mRNA expression of SST was significantly reduced by 38% in female subjects and by 27% in male subjects with MDD. The characteristic age-related decline in SST expression was observed in control (Pearson R=-0.357, p=0.005) but not MDD (R=-0.104, p=0.234) subjects, as low expression was detected across ages in MDD subjects. Protein expression was similarly reduced by 19% in both MDD groups, and findings were more robust in female (p=0.0056) than in males (p=0.0373) compared to respective controls. In conclusion, low SST represents a robust pathological finding in MDD. Specifically, alterations in SST signaling and/or SST-bearing GABA neurons may represent a critical pathophysiological entity that contributes to sgACC dysfunction and that matches to the high female vulnerability to develop MDD.
Copyright © 2010 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21232602      PMCID: PMC3039077          DOI: 10.1016/j.nbd.2011.01.014

Source DB:  PubMed          Journal:  Neurobiol Dis        ISSN: 0969-9961            Impact factor:   5.996


  57 in total

1.  Combining probability from independent tests: the weighted Z-method is superior to Fisher's approach.

Authors:  M C Whitlock
Journal:  J Evol Biol       Date:  2005-09       Impact factor: 2.411

2.  Anterior cingulate and subgenual prefrontal blood flow changes following tryptophan depletion in healthy males.

Authors:  Peter S Talbot; Stephen J Cooper
Journal:  Neuropsychopharmacology       Date:  2006-01-11       Impact factor: 7.853

Review 3.  Pathophysiologically based treatment interventions in schizophrenia.

Authors:  David A Lewis; Guillermo Gonzalez-Burgos
Journal:  Nat Med       Date:  2006-09       Impact factor: 53.440

4.  GABAergic neurons immunoreactive for calcium binding proteins are reduced in the prefrontal cortex in major depression.

Authors:  Grazyna Rajkowska; Gillian O'Dwyer; Zsofia Teleki; Craig A Stockmeier; Jose Javier Miguel-Hidalgo
Journal:  Neuropsychopharmacology       Date:  2006-10-25       Impact factor: 7.853

5.  Parvalbumin neurons in the entorhinal cortex of subjects diagnosed with bipolar disorder or schizophrenia.

Authors:  Harry Pantazopoulos; Nicholas Lange; Ross J Baldessarini; Sabina Berretta
Journal:  Biol Psychiatry       Date:  2006-09-01       Impact factor: 13.382

Review 6.  Somatostatinergic systems in brain: networks and functions.

Authors:  Cécile Viollet; Gabriel Lepousez; Catherine Loudes; Catherine Videau; Axelle Simon; Jacques Epelbaum
Journal:  Mol Cell Endocrinol       Date:  2007-09-22       Impact factor: 4.102

7.  Alterations in somatostatin mRNA expression in the dorsolateral prefrontal cortex of subjects with schizophrenia or schizoaffective disorder.

Authors:  Harvey M Morris; Takanori Hashimoto; David A Lewis
Journal:  Cereb Cortex       Date:  2008-01-17       Impact factor: 5.357

8.  Conserved regional patterns of GABA-related transcript expression in the neocortex of subjects with schizophrenia.

Authors:  Takanori Hashimoto; H Holly Bazmi; Karoly Mirnics; Qiang Wu; Allan R Sampson; David A Lewis
Journal:  Am J Psychiatry       Date:  2008-02-15       Impact factor: 18.112

9.  Changes in density of calcium-binding-protein-immunoreactive GABAergic neurons in prefrontal cortex in schizophrenia and bipolar disorder.

Authors:  Tsutomu Sakai; Akihiko Oshima; Yusuke Nozaki; Itsuro Ida; Chie Haga; Haruhiko Akiyama; Yoichi Nakazato; Masahiko Mikuni
Journal:  Neuropathology       Date:  2007-12-05       Impact factor: 1.906

Review 10.  How can drug discovery for psychiatric disorders be improved?

Authors:  Yves Agid; György Buzsáki; David M Diamond; Richard Frackowiak; Jay Giedd; Jean-Antoine Girault; Anthony Grace; Jeremy J Lambert; Husseini Manji; Helen Mayberg; Maurizio Popoli; Alain Prochiantz; Gal Richter-Levin; Peter Somogyi; Michael Spedding; Per Svenningsson; Daniel Weinberger
Journal:  Nat Rev Drug Discov       Date:  2007-03       Impact factor: 84.694

View more
  80 in total

1.  Developmental influence of the serotonin transporter on the expression of npas4 and GABAergic markers: modulation by antidepressant treatment.

Authors:  Gianluigi Guidotti; Francesca Calabrese; Francesca Auletta; Jocelien Olivier; Giorgio Racagni; Judith Homberg; Marco A Riva
Journal:  Neuropsychopharmacology       Date:  2011-10-19       Impact factor: 7.853

2.  Reduced GABAergic cortical inhibition in aging and depression.

Authors:  Jennifer I Lissemore; Apoorva Bhandari; Benoit H Mulsant; Eric J Lenze; Charles F Reynolds; Jordan F Karp; Tarek K Rajji; Yoshihiro Noda; Reza Zomorrodi; Etienne Sibille; Zafiris J Daskalakis; Daniel M Blumberger
Journal:  Neuropsychopharmacology       Date:  2018-05-17       Impact factor: 7.853

3.  GABAergic control of depression-related brain states.

Authors:  Bernhard Luscher; Thomas Fuchs
Journal:  Adv Pharmacol       Date:  2015-01-14

4.  The Role of Dendritic Brain-Derived Neurotrophic Factor Transcripts on Altered Inhibitory Circuitry in Depression.

Authors:  Hyunjung Oh; Sean C Piantadosi; Brad R Rocco; David A Lewis; Simon C Watkins; Etienne Sibille
Journal:  Biol Psychiatry       Date:  2018-10-09       Impact factor: 13.382

Review 5.  Altered Connectivity in Depression: GABA and Glutamate Neurotransmitter Deficits and Reversal by Novel Treatments.

Authors:  Ronald S Duman; Gerard Sanacora; John H Krystal
Journal:  Neuron       Date:  2019-04-03       Impact factor: 17.173

6.  The Role of BDNF in Age-Dependent Changes of Excitatory and Inhibitory Synaptic Markers in the Human Prefrontal Cortex.

Authors:  Hyunjung Oh; David A Lewis; Etienne Sibille
Journal:  Neuropsychopharmacology       Date:  2016-07-15       Impact factor: 7.853

Review 7.  A role for the neuropeptide somatostatin in the neurobiology of behaviors associated with substances abuse and affective disorders.

Authors:  Stacey L Robinson; Todd E Thiele
Journal:  Neuropharmacology       Date:  2020-02-03       Impact factor: 5.250

8.  Opposite Molecular Signatures of Depression in Men and Women.

Authors:  Marianne L Seney; Zhiguang Huo; Kelly Cahill; Leon French; Rachel Puralewski; Joyce Zhang; Ryan W Logan; George Tseng; David A Lewis; Etienne Sibille
Journal:  Biol Psychiatry       Date:  2018-02-19       Impact factor: 13.382

9.  Laminar and cellular analyses of reduced somatostatin gene expression in the subgenual anterior cingulate cortex in major depression.

Authors:  Marianne L Seney; Adam Tripp; Samuel McCune; David A Lewis; Etienne Sibille
Journal:  Neurobiol Dis       Date:  2014-10-12       Impact factor: 5.996

Review 10.  Biological substrates underpinning diagnosis of major depression.

Authors:  Etienne Sibille; Beverly French
Journal:  Int J Neuropsychopharmacol       Date:  2013-05-14       Impact factor: 5.176

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.